在CYP2D6多态 rs1065852显著增加2型糖尿病的风险
1Medical College of Yan'an University, Yan'an, China.
Annals of medicine
|March 3, 2025
概括
在CYP2D6的遗传变异,特别是rs1065852多态,与2型糖尿病 (T2DM) 的风险增加有关. 这一发现突出了T2DM易感性的潜在遗传标志物.
科学领域:
- 遗传学 遗传学 是一个
- 代谢疾病 代谢疾病
- 药物基因组学 药物基因组学
背景情况:
- 细胞染色体P450 (CYP) 基因变异影响2型糖尿病 (T2DM) 易感性.
- 调查与T2DM风险相关的特定CYP基因变异,如CYP2C8和CYP2D6,对于了解疾病病因至关重要.
研究的目的:
- 检查CYP2C8和CYP2D6中的遗传多态化与发展T2DM的风险之间的关联.
- 确定可能使个体易患T2DM的潜在遗传标记.
主要方法:
- 采用了病例控制研究设计,包括512名T2DM患者和515名健康对照.
- 使用Agena MassARRAY系统进行了CYP2C8和CYP2D6多态的基因定型.
- 使用后勤回归和多因素缩小维度 (MDR) 分析来评估遗传关联和相互作用.
主要成果:
- 在CYP2D6中的rs1065852多态性显著与T2DM风险增加有关,特别是在男性和59岁以下的个体中.
- 研究的CYP2C8多态和T2DM风险之间没有发现显著的关联.
- 在MDR分析中,rs1065852被确定为T2DM的独立风险因素.
结论:
- 在CYP2D6基因的rs1065852变异被确定为T2DM的独立风险因素.
- 建议进行进一步的研究,以验证这些发现,并探索它们对T2DM风险评估和管理的临床影响.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

